Lantern Pharma (NASDAQ: LTRN) has entered into a definitive agreement for a registered direct offering expected to raise approximately $4 million in gross proceeds, with the potential for an additional $4 million through a concurrent private placement. The company will sell 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. In the private placement, Lantern will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share. The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions, with Rodman & Renshaw LLC acting as exclusive placement agent.
The transaction matters because it provides Lantern Pharma with immediate capital to advance its pipeline of oncology drug candidates, which are being developed using its proprietary RADR artificial intelligence and machine-learning platform. RADR is designed to transform the cost, pace, and precision of oncology drug development by integrating large-scale genomic and biological data to identify patients most likely to benefit from Lantern's therapies. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The net proceeds will be used for working capital and other general corporate purposes, giving Lantern flexibility to continue clinical development and potentially reach key milestones.
The unregistered warrants will become exercisable subject to stockholder approval and will expire five years following that approval. If fully exercised for cash, the private placement could generate an additional $4 million, bringing total potential gross proceeds to approximately $8 million. This dual structure balances immediate funding with potential future capital, while the stockholder approval requirement ensures compliance with Nasdaq rules. For investors, the offering demonstrates Lantern's ability to access capital markets despite challenging conditions for clinical-stage biotechs, and it underscores confidence in the company's AI-driven approach.
Lantern's RADR platform is central to its strategy, aiming to reduce the time and cost of drug development while increasing the probability of clinical success. By leveraging machine learning, Lantern seeks to identify biomarkers and patient populations that are most responsive to its therapies, a key differentiator in the competitive oncology space. The company's focus on rare and difficult-to-treat cancers, combined with its AI capabilities, positions it to potentially deliver more targeted and effective treatments.
For ongoing updates on Lantern Pharma, the company's newsroom is available at https://ibn.fm/LTRN. The full press release can be accessed at https://ibn.fm/PCJbt. InvestorWire, a specialized communications platform, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides wire-grade press release syndication, article and editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. These services help companies like Lantern Pharma reach a wide audience of investors and stakeholders.
The offering's success will depend on market conditions and stockholder approval for the warrants. If approved, the additional capital could extend Lantern's runway and support its mission to revolutionize oncology drug development. As a clinical-stage company, Lantern's ability to secure funding is critical, and this transaction reflects both the challenges and opportunities in the biotech financing landscape.
